Specialty Pharmacy

Allison Burns, Pharm.D., RPh, honored as the 2020 Next-Generation Pharmacist®.

Cholesterol-lowering statins have been found to potentially reduce the risk of cancer via a pathway that is unrelated to its impact on cholesterol, according to a recent study.

The FDA granted fast track designation to the investigational CD20-directed monoclonal antibody ublituximab in combination with the PI3K-delta inhibitor umbralisib for the treatment of chronic lymphocytic leukemia.

Patients with current or former smoking status may be at an increased risk of severe illness due to COVID-19.

The FDA granted osimertinib (Tagrisso) priority review designation for the adjuvant treatment of patients with early-stage EGFR-mutated non–small cell lung cancer following complete tumor resection with curative intent.

oNKord is a natural killer cellular immunotherapy product, meaning it can play an important role in controlling and curing both solid and hematological malignancies.

Pembrolizumab (Keytruda) has demonstrated promising activity when used in combination with chemotherapy or quavonlimab in select patients with nonsquamous non–small cell lung cancer.

Sirolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection.

The FDA action was based on results from the Phase 3 CheckMate -9ER trial evaluating nivolumab in combination with cabozantinib compared with sunitinib among patients with previously untreated advanced RCC.

Venetoclax was granted accelerated approval in November 2018, as well as priority review, breakthrough designation, and orphan drug designation.

In a short time, COVID-19 has increased our dependency on technology and pharmaceutical companies are actively investigating this digital transformation.

Women diagnosed with cancer as adolescents or young adults can be especially vulnerable to the impact of the disease and its treatment on their ability to work.

The FDA approved an expanded label for for pembrolizumab for adult patients with relapsed or refractory classical Hodgkin lymphoma.

Copanlisib (Aliqopa) in combination with rituximab (Rituxan) prolonged progression-free survival in patients with non-Hodgkin lymphoma who relapsed following 1 or more previous lines of rituximab-based therapy.

Despite it being fall, sun safety is important all year and even needs to be considered for winter sport activities, such as snowboarding and skiing.

Evidence-based cancer regimens have been shown to result in better outcomes, including longer survival and less toxicity.

Pacritinib is a JAK2/FLT3 inhibitor for the treatment of patients with myelofibrosis and severe thrombocytopenia defined as platelet counts of less than 50,000 μL.

The COVID-19 pandemic has caused many routine colorectal cancer screenings to be delayed.

In the absence of a direct head-to-head clinical trial, study may help inform treatment selections for stem cell transplant-ineligible patients.

The research found that obese patients with diabetes were significantly less likely to develop pancreatic cancer if they had undergone bariatric surgery, with the majority of the patients in the study being female.

Enfortumab vedotin-ejfv (Padcev) elicited durable responses in patients with locally advanced or metastatic urothelial cancer who received previous treatment with a PD-1/PD-L1 inhibitor.

The authors concluded that a single dose of targeted intraoperative radiotherapy should be an option accessible to health care providers and discussed with patients.

On Women Pharmacists Day, 5 industry leaders discuss work-life balance, job advancement, and mentorship.

Several risk factors for multiple sclerosis, such as disease progression and fatigue, increase the risk of unemployment.

Bacteria in the gut may play a role in the treatment outcomes of patients with prostate cancer taking oral medications, according to a recent study.

To celebrate American Pharmacists Month, Pharmacy Times spoke with several pharmacists about their experiences during the COVID-19 pandemic and how they have tackled its unique challenges.

Specialty pharmacies are uniquely positioned to thrive in the era of value-based health care.

During American Pharmacists Month, and as the country uses all available health care resources to address COVID-19, there has never been a better or more important time to grant provider status to pharmacists.

Study findings align with recent recommendations from the National Comprehensive Cancer Network for preventing febrile neutropenia in patients with early-stage breast cancer.

An overview of arrangements that pharmacies enter into that violate the federal anti-kickback statute.